검색어: sofosbuvir (슬로바키아어 - 영어)

ledipasvir/sofosbuvir
antibiotics

sof = sofosbuvir, b.
sof = sofosbuvir; b.

sofosbuvir: auc: ↑ 47
sofosbuvir: auc: ↑ 47%

atripla a sofosbuvir
interaction not studied.

liečivo je sofosbuvir.
the active substance is sofosbuvir.

+ sofosbuvir n = 286 n (%)
n = 286 n (%)

sofosbuvir 400 mg jedenkrát
sofosbuvir 400 mg once daily (daclatasvir 60 mg once daily)

12 týždňov smv + sofosbuvir
12 weeks smv + sofosbuvir

boceprevir, ledipasvir/sofosbuvir
boceprevir, ledipasvir/sofosbuvir

sofosbuvir/tenofovir- dizoproxilfumarát
sofosbuvir/tenofovir disoproxil fumarate

sofosbuvir je nukleotidový prekurzor.
sofosbuvir is a nucleotide prodrug.

12 týždňov olysio + sofosbuvir
12 weeks olysio + sofosbuvir

liečivá sú ledipasvir a sofosbuvir.
the active substances are ledipasvir and sofosbuvir.

24 týždňov olysio + sofosbuvir alebo
24 weeks olysio + sofosbuvir or

12 týždňov olysio + sofosbuvir + ribavirín2
12 weeks olysio + sofosbuvir + ribavirin2

sovaldi 400 mg filmom obalené tablety sofosbuvir
sovaldi 400 mg film-coated tablets sofosbuvir

sofosbuvir je povolený od januára 2014 ako liek sovaldi.
sofosbuvir has been authorised as sovaldi since january 2014.

0,025 mg)/sofosbuvir (400 mg jedenkrát denne)d
0.025 mg)/ sofosbuvir (400 mg once daily)d

daklinza + sofosbuvir (bez ribavirínu) počas 24 týždňov
daklinza + sofosbuvir (without ribavirin) for 24 weeks

epclusa sa nemá súbežne podávať s inými liekmi obsahujúcimi sofosbuvir.
epclusa should not be administered concurrently with other medicinal products containing sofosbuvir.